Dual BRAF/MEK inhibition with dabrafenib/trametinib therapy led to a significant and durable partial response in a treatment-refractory patient with unresectable, metastatic well-differentiated pancreatic neuroendocrine tumor grade 3. This evidence concerns the gene BRAF and pancreatic neuroendocrine tumor.